Literature DB >> 29863285

RNA sequencing confirms similarities between PPI-responsive oesophageal eosinophilia and eosinophilic oesophagitis.

K A Peterson1, M Yoshigi2, M W Hazel1, D A Delker1, E Lin3, C Krishnamurthy1, N Consiglio4, J Robson2, M Yandell3,5, F Clayton6.   

Abstract

BACKGROUND: Although current American guidelines distinguish proton pump inhibitor-responsive oesophageal eosinophilia (PPI-REE) from eosinophilic oesophagitis (EoE), these entities are broadly similar. While two microarray studies showed that they have similar transcriptomes, more extensive RNA sequencing studies have not been done previously. AIM: To determine whether RNA sequencing identifies genetic markers distinguishing PPI-REE from EoE.
METHODS: We retrospectively examined 13 PPI-REE and 14 EoE biopsies, matched for tissue eosinophil content, and 14 normal controls. Patients and controls were not PPI-treated at the time of biopsy. We did RNA sequencing on formalin-fixed, paraffin-embedded tissue, with differential expression confirmation by quantitative polymerase chain reaction (PCR). We validated the use of formalin-fixed, paraffin-embedded vs RNAlater-preserved tissue, and compared our formalin-fixed, paraffin-embedded EoE results to a prior EoE study.
RESULTS: By RNA sequencing, no genes were differentially expressed between the EoE and PPI-REE groups at the false discovery rate (FDR) ≤0.01 level. Compared to normal controls, 1996 genes were differentially expressed in the PPI-REE group and 1306 genes in the EoE group. By less stringent criteria, only MAPK8IP2 was differentially expressed between PPI-REE and EoE (FDR = 0.029, 2.2-fold less in EoE than in PPI-REE), with similar results by PCR. KCNJ2, which was differentially expressed in a prior study, was similar in the EoE and PPI-REE groups by both RNA sequencing and real-time PCR.
CONCLUSION: Eosinophilic oesophagitis and PPI-REE have comparable transcriptomes, confirming that they are part of the same disease continuum.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29863285      PMCID: PMC6019190          DOI: 10.1111/apt.14825

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  28 in total

1.  Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis.

Authors:  Alfredo J Lucendo; Ángel Arias; Jesús González-Cervera; José María Olalla; Javier Molina-Infante
Journal:  J Allergy Clin Immunol       Date:  2015-09-12       Impact factor: 10.793

2.  Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis.

Authors:  Jamie Sodikoff; Ikuo Hirano
Journal:  J Allergy Clin Immunol       Date:  2015-08-25       Impact factor: 10.793

3.  High Prevalence of Response to Proton-pump Inhibitor Treatment in Children With Esophageal Eosinophilia.

Authors:  Carolina Gutiérrez-Junquera; Sonia Fernández-Fernández; M Luz Cilleruelo; Ana Rayo; Luis Echeverría; Sergio Quevedo; Teresa Bracamonte; Enriqueta Román
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-05       Impact factor: 2.839

4.  The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor.

Authors:  G Vazquez-Elizondo; S Ngamruengphong; M Khrisna; K R Devault; N J Talley; S R Achem
Journal:  Aliment Pharmacol Ther       Date:  2013-10-05       Impact factor: 8.171

Review 5.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

6.  Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis.

Authors:  Kathryn A Peterson; Kristen L Thomas; Kristen Hilden; Lyska L Emerson; Jason C Wills; John C Fang
Journal:  Dig Dis Sci       Date:  2009-06-18       Impact factor: 3.199

7.  Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis.

Authors:  Wael N Sayej; Raza Patel; Robert D Baker; Eduardo Tron; Susan S Baker
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-10       Impact factor: 2.839

Review 8.  Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis.

Authors:  Stuart Jon Spechler; Robert M Genta; Rhonda F Souza
Journal:  Am J Gastroenterol       Date:  2007-06       Impact factor: 10.864

9.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome.

Authors:  Bo Li; Colin N Dewey
Journal:  BMC Bioinformatics       Date:  2011-08-04       Impact factor: 3.307

10.  Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells.

Authors:  Xi Zhang; Edaire Cheng; Xiaofang Huo; Chunhua Yu; Qiuyang Zhang; Thai H Pham; David H Wang; Stuart J Spechler; Rhonda F Souza
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more
  4 in total

1.  Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features.

Authors:  Zachary M Dong; Edwin Lin; Michael E Wechsler; Peter F Weller; Amy D Klion; Bruce S Bochner; Don A Delker; Mark W Hazel; Keke Fairfax; Paneez Khoury; Praveen Akuthota; Peter A Merkel; Anne-Marie Dyer; Carol Langford; Ulrich Specks; Gerald J Gleich; Vernon M Chinchilli; Benjamin Raby; Mark Yandell; Frederic Clayton
Journal:  Am J Pathol       Date:  2020-04-03       Impact factor: 4.307

2.  Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study.

Authors:  Tetsuo Shoda; Ting Wen; Julie M Caldwell; Margaret H Collins; John A Besse; Garrett A Osswald; J Pablo Abonia; Nicoleta C Arva; Dan Atkins; Kelley E Capocelli; Evan S Dellon; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Vincent A Mukkada; Philip E Putnam; Rachel M Sheridan; Amanda K Rudman Spergel; Jonathan M Spergel; Joshua B Wechsler; Guang-Yu Yang; Seema S Aceves; Glenn T Furuta; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2019-11-16       Impact factor: 10.793

Review 3.  Models and Tools for Investigating Eosinophilic Esophagitis at the Bench.

Authors:  Amiko M Uchida; Gabrielle Ro; John J Garber; Kathryn A Peterson; June L Round
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

Review 4.  Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions.

Authors:  James P Franciosi; Edward B Mougey; Evan S Dellon; Carolina Gutierrez-Junquera; Sonia Fernandez-Fernandez; Rajitha D Venkatesh; Sandeep K Gupta
Journal:  J Asthma Allergy       Date:  2022-02-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.